Ten meta-analyses were incorporated into the review, and the combined findings of this study showed that SGLT-2 inhibitors are linked to significantly lower rates of cardiovascular death or heart failure hospitalization in patients with heart failure, cardiovascular death, all-cause mortality, and heart failure hospitalization outcomes. Here, SLC5A2 is linked to heart failure.